{'52WeekChange': -0.23483366,
 'SandP52WeekChange': None,
 'address1': '85 Dan Road',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.83,
 'askSize': 900,
 'averageDailyVolume10Day': 286300,
 'averageVolume': 216693,
 'averageVolume10days': 286300,
 'beta': None,
 'beta3Year': None,
 'bid': 3.75,
 'bidSize': 900,
 'bookValue': 0.382,
 'category': None,
 'circulatingSupply': None,
 'city': 'Canton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.99,
 'dayLow': 3.75,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -19.52,
 'enterpriseToRevenue': 1.74,
 'enterpriseValue': 462072768,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.813857,
 'fiftyTwoWeekHigh': 8.336,
 'fiftyTwoWeekLow': 2.472,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11606084,
 'forwardEps': -0.52,
 'forwardPE': -7.2307696,
 'fromCurrency': None,
 'fullTimeEmployees': 835,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.65300006,
 'heldPercentInstitutions': 0.27615,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/organogenesis.com',
 'longBusinessSummary': 'Organogenesis Holdings Inc., a regenerative medicine '
                        'company, focuses on the development, manufacture, and '
                        'commercialization of solutions for the advanced wound '
                        'care, and surgical and sports medicine markets '
                        "primarily in the United States. The company's "
                        'advanced wound care products include Apligraf for the '
                        'treatment of venous leg ulcers and diabetic foot '
                        'ulcers (DFUs); Dermagraft for treating DFUs; PuraPly '
                        'AM to address biofilm across a range of wound types; '
                        'and Affinity and NuShield to address various wound '
                        'sizes and types. Its surgical and sports medicine '
                        'products comprise ReNu for in-office joint and tendon '
                        'applications; NuCel for bony fusion in the spine and '
                        'extremities; NuShield and Affinity for surgical '
                        'applications in targeted soft tissue repairs; and '
                        'PuraPly AM for the surgical treatment of open wounds. '
                        "The company's pipeline products include TransCyte for "
                        'the treatment of second- and third-degree burns; '
                        'PuraForce, a bioengineered porcine collagen surgical '
                        'matrix for use in soft tissue reinforcement '
                        'applications; Novachor for the treatment of chronic '
                        'and acute wounds; Gintuit for the treatment of '
                        'mucogingival conditions in adults; and PuraPly XT and '
                        'PuraPly MZ for the treatment of chronic and acute '
                        'wounds, as well as for surgical treatment of open '
                        'wounds. It serves hospitals, wound care centers, '
                        'government facilities, ambulatory service centers, '
                        'and physician offices. The company sells its products '
                        'through direct sales representatives and independent '
                        'agencies. Organogenesis Holdings Inc. was founded in '
                        '1985 and is headquartered in Canton, Massachusetts.',
 'longName': 'Organogenesis Holdings Inc.',
 'market': 'us_market',
 'marketCap': 398966080,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_294048',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -41746000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.99,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 575 0775',
 'previousClose': 3.91,
 'priceHint': 4,
 'priceToBook': 9.842932,
 'priceToSalesTrailing12Months': 1.5021878,
 'profitMargins': -0.15475,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.99,
 'regularMarketDayLow': 3.75,
 'regularMarketOpen': 3.99,
 'regularMarketPreviousClose': 3.91,
 'regularMarketPrice': 3.99,
 'regularMarketVolume': 56653,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 106108000,
 'sharesPercentSharesOut': 0.0045,
 'sharesShort': 474430,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 354712,
 'shortName': 'Organogenesis Holdings Inc.',
 'shortPercentOfFloat': 0.0112,
 'shortRatio': 2.26,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ORGO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.433,
 'twoHundredDayAverage': 3.8965468,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '57bdb2b0-fbe2-332a-aca5-568eca4ff9a3',
 'volume': 56653,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://organogenesis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02021'}